Trial Profile

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria (CALM-CIndU)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INCB 000262 (Primary)
Indications Chronic urticaria; Cold Urticaria; Familial dermographism
Focus Adverse reactions; Proof of concept
Acronyms CALM-CIndU
Sponsors Escient Pharmaceuticals

Most Recent Events

09 Dec 2024 Status changed from active, no longer recruiting to completed.
29 Aug 2024 Status changed from recruiting to active, no longer recruiting.
25 Sep 2023 According to Escient Pharmaceuticals media release, the first subject has been dosed in CALM-CIndU trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com